Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2017 01:30 ET | Source: Oxurion NV

ThromboGenics Business Update - Q3 2017

Press release 20 October, 2017Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash received from...
October 09, 2017 01:30 ET | Source: Oxurion NV

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Press release Murine form of THR-317 able to reduce inflammation, vascular leakage and fibrosisin the mouse eye, without triggering a neurodegenerative response. Leuven, Belgium, 9th October 2017...
September 28, 2017 11:35 ET | Source: Oxurion NV

ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Press release Leuven, Belgium, 28th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic...
September 27, 2017 18:05 ET | Source: Oxurion NV

ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Leuven, Belgium, 27th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease,...
September 18, 2017 01:30 ET | Source: Oxurion NV

ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Leuven, Belgium, 18th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease,...
September 07, 2017 11:40 ET | Source: Oxurion NV

ThromboGenics Business Update - H1 2017

Press release 7 September, 2017Regulated Information Good Progress in Advancing Diabetic Eye Disease Portfolio Oncurious NV grows...
September 01, 2017 01:30 ET | Source: Oxurion NV

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Leuven, Belgium 1 September 2017 - ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today announces that it has reached principle...
August 16, 2017 01:30 ET | Source: Oxurion NV

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Leuven, Belgium, 16 August 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that further ocriplasmin...
July 10, 2017 01:30 ET | Source: Oxurion NV

ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement

Leuven, Belgium and Lund, Sweden - July 10, 2017 -ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB ("BioInvent") (OMXS: BINV) today announce that they have agreed to amend...
June 15, 2017 11:40 ET | Source: Oxurion NV

ThromboGenics Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors

Leuven, Belgium, 15 June 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announces that the Board has appointed...